化学性质：                                                                                                             

产品描述：                                                                                                            

Tocilizumab (Anti-Human IL6R) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R) is approved for the treatment of rheumatoid arthritis in Europe and the United States[1].

Tocilizumab (Anti-Human IL6R) (1, 10, and 100 ng/mL; 24 hours, 48 hours) inhibits the cell proliferation (growth rate) in a dose-dependent manner, growth rate by HACM is reduced almost completely by 100 ng/mL tocilizumab[2].Tocilizumab (Anti-Human IL6R) (0.001-10,000 μg/ml; 2 days) inhibits Ba/F3-gp130-IL-6R cell proliferation stimulated with hIL-6 with an IC50 of 13.5 ng/ml[1].Tocilizumab (Anti-Human IL6R) (1 μM; 6 hours) reduces the phosphorylation of STAT3 in vitro consistent with in vivo SAS cells[3].Tocilizumab (Anti-Human IL6R) (1-5 μM; 24 hours) significantly reduces VEGF mRNA expression in SAS cells with serum-free medium[3]. Cell Proliferation Assay[2] Cell Line: Human-derived HARA-B cells

Tocilizumab (Anti-Human IL6R) (intravenous injection; 1.0 mg/100 μL; twice a week, three weeks) decreases the volume of each metastatic focus in tocilizumab-injected mouse brains[2].Tocilizumab (Anti-Human IL6R) (intraperitoneal injection;100 μg/mL, every 48 hours; 20days) suppresses OSCC progression and suppresses Tumor Angiogenesis[3]. Animal Model: A brain metastasis model of lung tumor cells by inoculating HARA-B cells in nude mice[2]

[1]. Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011 Dec 16;286(50):42959-70. [2]. Mami Noda, et al. IL-6 Receptor Is a Possible Target against Growth of Metastasized Lung Tumor Cells in the Brain. Int J Mol Sci. 2013 Jan; 14(1): 515-526. [3]. Humanized Anti-Interleukin-6 Receptor Antibody Suppresses Tumor Angiogenesis and In vivo Growth of Human Oral Squamous Cell Carcinoma

特别提醒：